小児科におけるセルメチニブの治療薬モニタリング:LC-MS/MSとLC-HRMSの組み合わせによるアプローチ
Alessia Cafaro1, Andrea Santangelo2,3, Sebastiano Barco1
1Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Frontiers in pharmacology
|September 3, 2025
まとめ
新しい方法は,NF1患者のセルメチニブを正確に測定し,薬物の代謝の変化を明らかにします. これは,プレキシ型神経線維腫の個別化投与をサポートし,神経線維腫1型の治療を改善します.
科学分野:
- 薬理学について
- 分析化学
- 遺伝学
背景:
- 神経線維腫1型 (NF1) は,限られた治療で,プレキシ型神経線維腫 (PNs) を引き起こします.
- セルメチニブは,小児のNF1 PNsに対する標的療法ですが,その有効性は個々の代謝によって異なります.
- セルメチニブの薬理学を理解することは,治療の最適化に不可欠です.
研究 の 目的:
- セルメチニブをヒトのプラズマで定量化するための新しいLC-MS/MS方法を開発し,検証する.
- LC-HRMSを用いてセルメチニブ代謝物のプロファイリングにより,個別間での薬理学的変動性を調査する.
- NF1患者の小児における開発方法の臨床的適用性を評価する.
主な方法:
- ICH M10ガイドラインに従って,セルメチニブをヒトの血で定量化するための新しい液体染色体- タンドム質量測定法 (LC- MS/ MS) を検証した.
- 患者の血におけるセルメチニブメタボリットを特定し,プロファイルするために,液体染色体高解像度質量スペクトロメトリ (LC- HRMS) を適用した.
- 治療中の小児NF1患者のセルメチニブCの低濃度測定
主要な成果:
- LC- MS/ MSメソッドは,セルメチニブの定量化において高い選択性,精度,および正確性を示した.
- NF1の小児患者におけるセルメチニブCの最低濃度は15. 80から537. 39ng/ mlであった.
- 有効なN- デスメチル- セルメチニブ (M8) を含む10のセルメチニブ代謝産物が見つかり,患者間では代謝産物対原産物比 (MPR) が有意に異なった.
結論:
- 開発されたLC- MS/ MSおよびLC- HRMS方法は,セルメチニブの正確な定量化と,患者特有の代謝プロフィールの洞察を提供します.
- この分析戦略はセルメチニブの治療薬モニタリング (TDM) をサポートします.
- この発見は,NF1患者のセルメチニブ投与戦略の個別化への道を開く.
関連する概念動画
Therapeutic Drug Monitoring: Overview and Classification
642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642
Therapeutic Drug Monitoring: Drug Analysis Methods
342
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
342
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution
554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408


